825 followers
A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for… http://t.co/PYTZCwDPvJ
A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative…
Overview of attention for article published in Pancreatology, July 2014